Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

NCT06635824 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

191

Enrollment

INDUSTRY

Sponsor class

Conditions

PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

Interventions

DRUG: Acasunlimab
DRUG: Pembrolizumab
DRUG: Docetaxel

Sponsor

Genmab